ClinicalTrials.gg
RecruitingNCT07135089INSIST-IT2Updated Dec 9, 2025

Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban

A Phase 3 interventional study of Intravenous tirofiban before endovascular thrombectomy and Intravenous placebo before endovascular thrombectomy in Stroke, Ischemic, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by General Hospital of Shenyang Military Region · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
870
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.

Planned enrollment
5th of 27
870 · median 145
Started
2025
with 4 others
Phase 3
4 of 34
1 open now
Primary completion
2027-09
later than 5 of 15 live
Registered
28th of 34
by date

Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 5th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 5 of the 15 other live ones, and was the 28th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, or all of them as a file.
02

Study summary

It remains uncertain whether intravenous tirofiban administered before endovascular thrombectomy could improve disability severity for patients with LVO due to intracranial atherosclerosis.The current study aimed to assess the efficacy and safety of administering intravenous tirofiban before endovascular thrombectomy for improving clinical outcomes in patients with anterior circulation LVO due to intracranial atherosclerosis.

03

Conditions studied

  • Stroke, Ischemic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Anterior circulation large vessel occlusion (the internal carotid artery or the first or second segment of the middle cerebral artery) confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA);
  • Eligible for endovascular treatment within 12 hours of symptom onset;
  • Based on the patient's medical history, clinical presentation, and imaging findings, large artery atherosclerosis is highly suspected as the underlying etiology;
  • Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;
  • Baseline ASPECTS ≥ 6 on CT;
  • A pre-stroke modified Rankin Scale (mRS) score of ≤2;
  • Signed by patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation or atrial flutter, or 12-lead before randomization and after admission showing atrial flutter or atrial fibrillation;
  • Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage, or a history of bleeding within one month;
  • Intracranial aneurysms or malformations, tortuous arteries that hinder thrombectomy, and space-occupying effect brain tumors;
  • The following drugs are taken within one week: dual antiplatelet drugs, direct oral anticoagulants (DOACs), warfarin and other drugs that increase the risk of bleeding;
  • Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);
  • Deficiency of anticoagulant factors or (INR) > 1.7, count \< 90×10⁹/L;;
  • Severe renal insufficiency and advanced disease with an expected of less than 6 months;
  • Pregnancy or lactation;
  • Allergy to drugs or contrast agents;
  • Participating in other clinical trials;
  • Other conditions that the researcher deems unsuitable for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
870 participants (estimated)

Study arms

  • Experimental
    Tirofiban group

    Intravenous tirofiban before endovascular thrombectomy

    Drug: Intravenous tirofiban before endovascular thrombectomy

  • Placebo comparator
    Placebo group

    Intravenous placebo before Endovascular Thrombectomy

    Drug: Intravenous placebo before endovascular thrombectomy

Interventions

  • DrugIntravenous tirofiban before endovascular thrombectomy

    The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.

  • DrugIntravenous placebo before endovascular thrombectomy

    The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with functional independence (modified Rankin Scale [mRS] score of 0 to 2)

    mRS ranges from 0-6, with high score meaning poor outcome

    Time frame: Day 90

Secondary outcomes

  1. The proportion of patients without disability (modified Rankin Scale [mRS] score of 0 to 1) or who returned to their premorbid mRS score at 90 days (for patients with prestroke mRS score >1)

    mRS ranges from 0-6, with high score meaning poor outcome

    Time frame: Day 90

  2. ordinal distribution of modified Rankin Scale (mRS)

    mRS ranges from 0-6, with high score meaning poor outcome

    Time frame: Day 90

  3. The proportions of patients with substantial reperfusion at initial preprocedure catheter angiogram (defined as mTICI score ≥2b)

    Substantial reperfusion was defined as an expanded Thrombolysis In Cerebral Infarction grade of 2b50 (substantial reperfusion), 2c (nearcomplete reperfusion), or 3 (complete reperfusion).

    Time frame: immediately after first catheter angiogram

  4. The proportions of patients with substantial reperfusion at final angiogram

    Time frame: immediately after final angiogram

  5. The proportions of patients with complete recanalization as assessed by CTA or MRA 48 hours after endovascular treatment

    Time frame: 24 (-6/+24) hours

  6. Change in National Institute of Health stroke scale (NIHSS)

    NIHSS ranges from 0-42, with high score meaning poor outcome

    Time frame: 24 (-6/+24) hours

  7. change in National Institute of Health stroke scale (NIHSS)

    NIHSS ranges from 0-42, with high score meaning poor outcome

    Time frame: 7 (-2/+2) days

  8. The incidence of symptomatic intracranial hemorrhage assessed according to Heidelberg bleeding classification

    Time frame: 24 (-6/+24) hours

  9. The incidence of intraparenchymal hemorrhage (PH1 and PH2)

    Time frame: 24 (-6/+24) hours

  10. The incidence of non-intracranial hemorrhage complications

    Time frame: 24 (-6/+24) hours

  11. Serious adverse events

    eg, acute respiratory failure, large or malignant middle cerebral artery infarction, acute heart failure, hemicraniectomy

    Time frame: 7 (-2/+2) days

  12. Procedure-associated complications

    Time frame: Periprocedural

  13. The proportion of patients with thrombocytopenia

    Time frame: 24 (-6/+24) hours

  14. The incidence of mortality

    Time frame: Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 22 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 21, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07135089
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Aug 21, 2025
Start date
Nov 13, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

Hui-Sheng Chen
Contact
chszh@aliyun.com
+86-024-28897511

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion